ImmunityBio (NASDAQ:IBRX) Sees Large Volume Increase

ImmunityBio, Inc. (NASDAQ:IBRX) shares saw unusually-high trading volume on Monday . Approximately 2,288,619 shares traded hands during mid-day trading, a decline of 38% from the previous session’s volume of 3,683,848 shares.The stock last traded at $1.31 and had previously closed at $1.29.

ImmunityBio Stock Up 19.0 %

The firm’s fifty day simple moving average is $2.12 and its two-hundred day simple moving average is $2.37.

ImmunityBio (NASDAQ:IBRX) last posted its earnings results on Tuesday, August 8th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The business had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.03 million. Equities research analysts predict that ImmunityBio, Inc. will post -1.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ImmunityBio

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Western Wealth Management LLC purchased a new stake in shares of ImmunityBio in the 2nd quarter valued at approximately $58,000. California State Teachers Retirement System raised its stake in shares of ImmunityBio by 11.6% in the 2nd quarter. California State Teachers Retirement System now owns 151,684 shares of the company’s stock valued at $422,000 after acquiring an additional 15,751 shares during the period. Alliancebernstein L.P. increased its stake in ImmunityBio by 18.9% during the 2nd quarter. Alliancebernstein L.P. now owns 299,010 shares of the company’s stock worth $831,000 after buying an additional 47,452 shares during the period. Wells Fargo & Company MN increased its stake in ImmunityBio by 93.2% during the 2nd quarter. Wells Fargo & Company MN now owns 63,953 shares of the company’s stock worth $178,000 after buying an additional 30,850 shares during the period. Finally, Fishman Jay A Ltd. MI increased its stake in ImmunityBio by 44.6% during the 2nd quarter. Fishman Jay A Ltd. MI now owns 162,000 shares of the company’s stock worth $450,000 after buying an additional 50,000 shares during the period. 8.60% of the stock is owned by hedge funds and other institutional investors.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, toll-Like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers.